- Home
- BRCB vs MESO Comparison
BRCB vs MESO Comparison
Compare BRCB & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRCB
- MESO
- Stock Information
- Founded
- BRCB 2008
- MESO 2004
- Country
- BRCB United States
- MESO Australia
- Employees
- BRCB N/A
- MESO N/A
- Industry
- BRCB
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRCB
- MESO Health Care
- Exchange
- BRCB Nasdaq
- MESO Nasdaq
- Market Cap
- BRCB 1.3B
- MESO 1.3B
- IPO Year
- BRCB 2025
- MESO N/A
- Fundamental
- Price
- BRCB $25.66
- MESO $16.66
- Analyst Decision
- BRCB Buy
- MESO Buy
- Analyst Count
- BRCB 6
- MESO 2
- Target Price
- BRCB $28.40
- MESO $24.00
- AVG Volume (30 Days)
- BRCB 281.5K
- MESO 232.0K
- Earning Date
- BRCB 11-11-2025
- MESO 08-28-2025
- Dividend Yield
- BRCB N/A
- MESO N/A
- EPS Growth
- BRCB N/A
- MESO N/A
- EPS
- BRCB N/A
- MESO N/A
- Revenue
- BRCB $179,481,000.00
- MESO $17,198,000.00
- Revenue This Year
- BRCB $26.31
- MESO $288.50
- Revenue Next Year
- BRCB $27.30
- MESO $167.17
- P/E Ratio
- BRCB N/A
- MESO N/A
- Revenue Growth
- BRCB 20.84
- MESO 191.39
- 52 Week Low
- BRCB $20.39
- MESO $7.09
- 52 Week High
- BRCB $30.40
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- BRCB N/A
- MESO 47.29
- Support Level
- BRCB N/A
- MESO $16.10
- Resistance Level
- BRCB N/A
- MESO $18.94
- Average True Range (ATR)
- BRCB 0.00
- MESO 0.49
- MACD
- BRCB 0.00
- MESO -0.24
- Stochastic Oscillator
- BRCB 0.00
- MESO 19.72
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.